The Supreme Court’s term has delivered one of the most consequential rulings in mass tort history. On June 25, 2026, the Court issued its decision in Monsanto v. Durnell (No. 24-1068) — holding that FIFRA expressly preempts failure-to-warn tort claims contending pesticide labels should include cancer warnings different from EPA-approved labels. The ruling lands while roughly 65,000 Roundup lawsuit 2026 claims remain pending across the country, and its implications for cancer survivors who used the weedkiller for decades cannot be overstated.
What Is Monsanto v. Durnell and Why Does It Matter
John Durnell is a Missouri farmer who developed non-Hodgkin lymphoma after decades of applying Roundup to his fields. In 2023, a Missouri jury awarded him $1.25 million on a failure-to-warn claim — finding that Monsanto failed to adequately disclose glyphosate’s cancer risks on its label. The Missouri Court of Appeals affirmed that verdict in February 2025, the Missouri Supreme Court declined review on April 1, 2025, and Monsanto petitioned the U.S. Supreme Court just three days later. The Court granted certiorari on January 16, 2026, and heard oral arguments on April 27, 2026. On June 25, 2026, the Court issued its decision, siding with Monsanto and holding that FIFRA’s uniformity clause expressly preempts state failure-to-warn claims that seek cancer warnings different from those on EPA-approved labels.
The core legal question before the Court was whether the Federal Insecticide, Fungicide, and Rodenticide Act’s (FIFRA) uniformity clause — codified at 7 U.S.C. §136v(b) — expressly or impliedly preempts state-law failure-to-warn claims in cases where the EPA has not required a cancer warning on Roundup’s label. Monsanto argued its label was “preempted twice over”: once by the statute’s text, and again because EPA approval is required before any label change can take effect. The Court agreed on the express preemption ground. The ruling does not just end Durnell’s case — it strikes at the legal foundation underlying every pending Roundup lawsuit 2026 failure-to-warn claim in the country.
The stakes are enormous. Roughly 65,000 claimants remain in litigation — most in state courts, with about 3,900 in the federal MDL. For those claimants, and the millions more who used Roundup and had been weighing whether to file, the June 25 decision from One First Street is among the most consequential in the history of pesticide mass tort litigation. Whether viable alternative legal theories exist to sustain those remaining claims will now become the central question for plaintiffs’ attorneys nationwide.
The Preemption Battle: Express vs. Implied, and What the Justices Decided
Monsanto’s preemption argument rested on a structural tension that has divided courts for two decades. The EPA maintains that glyphosate is “not likely to be carcinogenic to humans.” The International Agency for Research on Cancer (IARC) reached the opposite conclusion in 2015, classifying glyphosate as “probably carcinogenic to humans.” State juries, applying state tort law, repeatedly sided with plaintiffs — and Monsanto sought to have that entire category of litigation shut down by federal supremacy. On June 25, 2026, the Supreme Court gave Monsanto much of what it asked for, ruling that FIFRA’s express preemption clause bars failure-to-warn claims that demand cancer warnings inconsistent with the EPA-approved label.
The Trump administration’s Department of Justice filed an amicus brief supporting Monsanto, with Principal Deputy Solicitor General Sarah Harris arguing that states cannot “second-guess or undermine” EPA’s pesticide registration decisions. That executive-branch alignment with a corporate defendant proved significant: the Court’s majority reasoning echoed the government’s position that state-court failure-to-warn verdicts represent an intrusion on EPA’s regulatory authority, regardless of how juries evaluate the underlying science.
The ruling also has a legislative echo. At least six states have already introduced bills to limit pesticide company liability by establishing uniformity between federal and state pesticide labeling requirements — a legislative push that now has significant judicial wind at its back following the Court’s decision. Critics warn this convergence of judicial and legislative pressure could effectively insulate pesticide manufacturers from accountability at both the state and federal level.
Durnell’s legal team, backed by Earthjustice and environmental advocates, had countered with the Supreme Court’s own 2005 precedent in Bates v. Dow Agrosciences, arguing that FIFRA’s savings clause preserves certain state-law claims. The majority distinguished Bates, holding that the specific failure-to-warn theory at issue here — demanding a cancer warning the EPA has expressly declined to require — falls squarely within FIFRA’s preemption clause rather than surviving under its savings clause. The decision is expected to draw scrutiny and potential legislative response from Congress, though no corrective bill has yet been introduced.
Bayer’s $7.25 Billion Settlement and What It Means After the Ruling
In February 2026, Bayer announced a $7.25 billion settlement to resolve thousands of Roundup lawsuits and establish a compensation program for current and future non-Hodgkin’s lymphoma victims. The deal was widely viewed at the time as a strategic hedge against the risk of continued trial losses — and against an unfavorable Supreme Court ruling. Now that the Court has sided with Monsanto on preemption, the settlement takes on new significance as one of the primary remaining avenues of compensation for claimants whose failure-to-warn theories have been federally foreclosed.
To date, Bayer has settled approximately 100,000 Roundup claims for roughly $11 billion across various settlement programs. The February 2026 agreement is the latest and most structured of those efforts, designed to capture both existing claimants and those who may be diagnosed in the future with non-Hodgkin’s lymphoma linked to glyphosate exposure. Whether the Supreme Court’s ruling affects the terms or participation incentives of the settlement program will likely be the subject of intense negotiation between Bayer and plaintiffs’ counsel in the coming months.
For claimants who opted out of earlier settlement programs, the June 25 ruling substantially narrows their litigation options. Failure-to-warn is the cornerstone theory in most Roundup cases, and its preemption leaves plaintiffs’ attorneys searching for alternative theories — such as design defect or manufacturing defect claims — that may survive federal preemption analysis. Whether those theories hold up in court remains to be seen, and Bayer is widely expected to argue they are equally foreclosed.
Key Statistics: The Roundup Litigation Landscape in 2026
The scale of Roundup litigation in 2026 is staggering, even after years of settlements. Consider the key numbers:
- 65,000 claims remain pending nationwide, with the majority in state courts and approximately 3,900 in the federal MDL.
- 24 trials have been completed, resulting in more than $8 billion awarded to plaintiffs across those verdicts.
- Bayer has settled approximately 100,000 claims for roughly $11 billion in total, including the February 2026 $7.25 billion program targeting current and future non-Hodgkin’s lymphoma victims.
- The Supreme Court’s June 25, 2026 ruling in Monsanto v. Durnell now directly threatens the failure-to-warn theory underlying the vast majority of the 65,000 remaining claims.
- At least six states have introduced legislation to align state pesticide labeling requirements with federal standards, limiting pesticide company liability at the state level as well.
These numbers tell a story of a litigation that has already delivered unprecedented accountability for a pesticide manufacturer — and that now faces an existential legal challenge that could prevent future claimants from recovering anything through the tort system.
What the Monsanto Win Means for Every Claimant
The Supreme Court’s ruling in Monsanto v. Durnell does not automatically dismiss every pending Roundup lawsuit, but it fundamentally reshapes the litigation landscape in ways that will be felt by every claimant still in the system. Here is what plaintiffs and their attorneys are now confronting:
Failure-to-warn claims are preempted. The Court held that FIFRA expressly bars state tort claims demanding cancer warnings that differ from EPA-approved labels. Because failure-to-warn is the primary — and in many cases the only — theory asserted in Roundup litigation, the ruling effectively eliminates the strongest basis for recovery for claimants who have not yet settled.
Alternative theories face long odds. Plaintiffs’ attorneys will now attempt to reframe remaining claims around design defect, manufacturing defect, or other non-warning-based theories. Whether those theories survive FIFRA preemption analysis under the majority’s reasoning is uncertain, and courts across the country will be litigating that question for years.
Settlement becomes more attractive — and more powerful for Bayer. With failure-to-warn preempted, Bayer’s negotiating leverage in settlement discussions increases substantially. Claimants who previously held out for trial may now find that the February 2026 settlement program represents their best — or only — realistic path to compensation.
Future claims may be barred at filing. For individuals who have not yet filed suit but believe their non-Hodgkin’s lymphoma was caused by Roundup exposure, the ruling creates a significant barrier. Any attorney they consult will need to assess whether a viable non-preempted theory exists before filing, and whether the statute of limitations in their state still permits a claim at all.
The political and legislative dimensions of this ruling will also play out over months and years. Consumer advocates and environmental groups are already calling on Congress to amend FIFRA to restore state-law remedies. Whether such legislation moves in the current Congress remains deeply uncertain.
Frequently Asked Questions: Roundup Lawsuit 2026
What is the current status of the Roundup lawsuit in 2026?
As of late June 2026, the Supreme Court has issued its decision in Monsanto v. Durnell, ruling that FIFRA expressly preempts state failure-to-warn claims seeking cancer warnings different from EPA-approved Roundup labels. Approximately 65,000 claims remain pending — most in state courts, with roughly 3,900 in the federal MDL. Bayer’s $7.25 billion settlement program, announced in February 2026, continues to process claims, and that program now represents the clearest path to compensation for many claimants in light of the Court’s ruling.
Did the opt-out deadline for the Roundup class settlement already pass?
Opt-out deadlines have varied by settlement program, and many earlier deadlines have already passed. Claimants who opted out of prior programs and were counting on trial verdicts face the greatest uncertainty following the Supreme Court’s preemption ruling. If you have questions about your specific situation, consulting with a mass tort attorney immediately is critical — the ruling may affect your strategic options in ways that require prompt action.
What does the Monsanto win at the Supreme Court mean for my Roundup claim?
If your claim is based on a failure-to-warn theory — which is the case for the vast majority of Roundup plaintiffs — the Supreme Court’s June 25, 2026 ruling in Monsanto v. Durnell creates a serious preemption barrier. Your attorney will need to assess whether any alternative non-preempted theory applies to your case and whether participation in Bayer’s $7.25 billion settlement program is available and advisable. The ruling does not automatically dismiss all Roundup claims, but it eliminates the strongest legal theory most plaintiffs have relied upon.
What is the Bates v. Dow Agrosciences precedent and why does it matter in 2026?
Bates v. Dow Agrosciences (2005) was the Supreme Court’s most significant prior ruling on FIFRA preemption. The Court held in Bates that FIFRA does not broadly preempt all state pesticide tort claims, and that certain state-law requirements that parallel federal requirements may survive. Roundup plaintiffs relied heavily on Bates to argue their failure-to-warn claims were not preempted. In Monsanto v. Durnell, the Court distinguished Bates, holding that claims demanding cancer warnings the EPA has affirmatively declined to require go beyond what Bates permits and fall within FIFRA’s express preemption clause. The 2026 ruling significantly narrows the scope of state tort claims that Bates was previously understood to preserve.
How much is a Roundup lawsuit claim worth in 2026?
Across 24 completed trials, juries have awarded more than $8 billion in total to Roundup plaintiffs, and Bayer has settled approximately 100,000 claims for roughly $11 billion. Individual settlement values have varied widely based on factors including the severity of the claimant’s non-Hodgkin’s lymphoma diagnosis, the extent of Roundup exposure, and the claimant’s age and medical history. Following the Supreme Court’s preemption ruling, the value of unsettled claims may decline as the strongest litigation theory has been foreclosed. Claimants still in the system should work closely with their attorneys to evaluate whether participation in Bayer’s $7.25 billion settlement program or continued litigation under alternative theories offers the better path forward.
Victoria Chambers is a mass tort and class action research analyst with extensive knowledge of multi-district litigation (MDL), defective product cases, dangerous drug lawsuits, and toxic exposure claims across the United States. Victoria is not an attorney and the information provided is for educational purposes only.